Immunohistochemical Studies on Galectin Expression in Colectomised Patients with Ulcerative Colitis.

Research output: Contribution to journalArticle

Standard

Immunohistochemical Studies on Galectin Expression in Colectomised Patients with Ulcerative Colitis. / Block, Mattias; Mölne, Johan; Leffler, Hakon; Börjesson, Lars; Breimer, Michael E.

In: BioMed Research International, Vol. 2016, 5989128, 2016.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

Block, Mattias ; Mölne, Johan ; Leffler, Hakon ; Börjesson, Lars ; Breimer, Michael E. / Immunohistochemical Studies on Galectin Expression in Colectomised Patients with Ulcerative Colitis. In: BioMed Research International. 2016 ; Vol. 2016.

RIS

TY - JOUR

T1 - Immunohistochemical Studies on Galectin Expression in Colectomised Patients with Ulcerative Colitis.

AU - Block, Mattias

AU - Mölne, Johan

AU - Leffler, Hakon

AU - Börjesson, Lars

AU - Breimer, Michael E

PY - 2016

Y1 - 2016

N2 - Introduction. The aetiology and pathogenesis of ulcerative colitis (UC) are essentially unknown. Galectins are carbohydrate-binding lectins involved in a large number of physiological and pathophysiological processes. Little is known about the role of galectins in human UC. In this immunohistochemical exploratory study, both epithelial and inflammatory cell galectin expression were studied in patients with a thoroughly documented clinical history and were correlated with inflammatory activity. Material and Methods. Surgical whole intestinal wall colon specimens from UC patients (n = 22) and controls (n = 10) were studied. Clinical history, pharmacological treatment, and modified Mayo-score were recorded. Tissue inflammation was graded, and sections were stained with antibodies recognizing galectin-1, galectin-2, galectin-3, and galectin-4. Results. Galectin-1 was undetectable in normal and UC colonic epithelium, while galectin-2, galectin-3, and galectin-4 were strongly expressed. A tendency towards diminished epithelial expression with increased inflammatory grade for galectin-2, galectin-3, and galectin-4 was also found. In the inflammatory cells, a strong expression of galectin-2 and a weak expression of galectin-3 were seen. No clear-cut correlation between epithelial galectin expression and severity of the disease was found. Conclusion. Galectin expression in patients with UC seems to be more dependent on disease focality and individual variation than on degree of tissue inflammation.

AB - Introduction. The aetiology and pathogenesis of ulcerative colitis (UC) are essentially unknown. Galectins are carbohydrate-binding lectins involved in a large number of physiological and pathophysiological processes. Little is known about the role of galectins in human UC. In this immunohistochemical exploratory study, both epithelial and inflammatory cell galectin expression were studied in patients with a thoroughly documented clinical history and were correlated with inflammatory activity. Material and Methods. Surgical whole intestinal wall colon specimens from UC patients (n = 22) and controls (n = 10) were studied. Clinical history, pharmacological treatment, and modified Mayo-score were recorded. Tissue inflammation was graded, and sections were stained with antibodies recognizing galectin-1, galectin-2, galectin-3, and galectin-4. Results. Galectin-1 was undetectable in normal and UC colonic epithelium, while galectin-2, galectin-3, and galectin-4 were strongly expressed. A tendency towards diminished epithelial expression with increased inflammatory grade for galectin-2, galectin-3, and galectin-4 was also found. In the inflammatory cells, a strong expression of galectin-2 and a weak expression of galectin-3 were seen. No clear-cut correlation between epithelial galectin expression and severity of the disease was found. Conclusion. Galectin expression in patients with UC seems to be more dependent on disease focality and individual variation than on degree of tissue inflammation.

U2 - 10.1155/2016/5989128

DO - 10.1155/2016/5989128

M3 - Article

VL - 2016

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 5989128

ER -